Bernstein just threw fresh fuel on Eli Lilly’s (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100.
For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price.
Analyst Courtney Breen feels Wall Street still isn’t factoring in how massive the company’s next wave of GLP-1 catalysts could be.
She feels Lilly’s incredible leap into the trillion-dollar club, as reported by Reuters, wasn’t the top, and that 2026 could be the turning point where its illustrious story transitions into genuine “beat-and-raise” momentum.
Also, orforglipron’s approaching launch, White House policy is moving towards broader coverage, while tirzepatide has evolved into becoming a multi-indication platform.
Hence, Breen sees a setup offering a ton of upside.
Moreover, it’s important to note that per Tipranks, Breen carries a standout 94% success rate, with 32 of her 34 stock calls turning a profit.
On top of that, her recommendations deliver a strong +21.5% average return per rating, positioning her among the top tier of Wall Street analysts.
Bernstein’s Courtney Breen lifted Eli Lilly’s price target significantly, citing stronger GLP-1 catalysts ahead.Photo by NurPhoto on Getty Images
Bernstein analyst Breen’s bullishness on Eli Lilly primarily rests on what she dubs as an “incredibly rich” catalyst path that stretches more than two years.
Most of it is down to how much earnings power Mr. Market hasn’t modeled into the stock.
At the center of it is Lilly’s oral GLP-1 orforglipron, which Breen feels will fuel the next leg of expansion for the company.
More Medicare/Medicaid
That’s in part due to a conducive U.S. policy backdrop that has shifted under President Donald Trump’s GLP-1 deal, along with growing global reimbursement channels.
Breen and her team developed a financial model slicing Medicare, Medicaid, commercial, and cash-pay demand on a quarterly schedule running through…
..
